Bernhard Hampl, Ph.D., has been appointed co-chairman of Cytovance Biologics, Inc. Previously, he served as chief executive officer of Eon Labs and the Sandoz U.S. division of Novartis. Dr. Hampl joined Eon as chief executive officer and president in 1996 and led the company’s growth transformation and subsequent acquisition by Novartis in 2005.

Darren Head, chief executive officer of Cytovance said, “Cytovance has been experiencing rapid business growth and the equity financing from Great Point Partners puts additional muscle on an already strong balance sheet that has no debt. As we expand our capabilities and facility in biologics contract manufacturing in both mammalian and microbial cell cultures for proteins and antibodies in the U.S. and internationally, we wanted to add an admired executive with global biologics and biosimilar manufacturing and marketing expertise. We are honored to have Dr. Hampl as Co-Chairman.”